people prescribed antidepressants are women
people received a mental health prescription in the UK during 2021
Studies have displayed psilocybin as a breakthrough for mental health care. Read about our natural psilocybin medicine: KRN-101.
Traditional clinical trial infrastructure means people currently suffering could be waiting 5 or more years for psilocybin therapy to be available to them.
Albert Labs is strategically placed in the UK, where innovative licensing and access programs are available. These programs also provide a pathway to the rest of the world.
UK clinical focus, supported by our Canadian and Portuguese research & development laboratories.
It is our promise to deliver our innovative mental health medicine to patients with urgent and unmet needs.
“Albert Labs’ first target product, KRN-101, is a potential solution for cancer-related anxiety, which affects over 15 million people across the world.”
Real-World Evidence can accelerate innovation and access for patients currently suffering from unmet needs. A clinical pathway previously used for Covid-19 vaccines and cancer treatments in the UK.
Leveraging existing clinic & research infrastructure and preidenitfied, accessible patient pools, through collaboration with established hospital networks.
Strategically placed in the UK to make use of the Real-World Evidence protocol, which provides crucial data and insights for licensing & regulation of prescribed medicine.
Patient-centric data and early clinician engagement will build and deliver these breakthroughs safely and effectively to those most in need.
Tens of millions of people are diagnosed with cancer each year, and millions more are living with it. The depression and anxiety that might accompany cancer is self-evident, more commonly known as cancer distress.
Worry, sleeplessness, fear, and doubts regarding the meaning of one’s life are commonplace with a cancer diagnosis.
Due to the complexities surrounding cancer therapy, too often, patients’ psychological needs are left untreated.
Albert Labs’ first target product, KRN-101, is a potential solution for cancer-related distress.
Everyone has been impacted by mental health and our expert team is no exception. We know the immense struggle and we endeavour to find better solutions for all.
Our people bring experience and expertise across multiple fields to deliver a scalable solution to the mental health crisis.
“Psychedelic therapy heals people. Thats really not something I’ve seen us do in psychiatry in all my career”
“I value Albert Labs’ emphasis on ethical and patient-centred investigations of the effectiveness of psychotherapy and psilocybin. ”
“It is an extremely exciting time for Albert Labs, we’re looking forward to treating our first patients with our product.”
Psilocybin is a naturally occuring tryptamine alkaloid found in over 200 species of fungi. It is a serotonin 2A receptor agonist, which after a single dose can have long-lasting beneficial effects on mood, personality, and potentially on mindfulness. Imagery found on prehistoric murals suggests that human usage of psilocybin mushrooms predates recorded history.
Albert Hofmann, a Swiss chemist, pioneered the development & isolation of psilocybin. Understanding its therapeutic value first-hand. 
Marketed by Sandoz as Indocybin™ for psychopharmacological and therapeutic clinical research. 
Albert Labs’ first target product, KRN-101, is a potential solution for cancer-related anxiety, which affects over 15 million people across the world.
© 2023 Albert Labs. All Rights Reserved
We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.
If you would like support or more information around making an investment, please contact [email protected]